






Supplementary Table S1


	PPAR γ	RXR α
Positive controls	 <p>Placenta</p>	 <p>Placenta</p>
Negative controls	 <p>Placenta</p>	 <p>Placenta</p>
materials	<p>Primary antibody: Anti-PPAR gamma; Rabbit IgG polyclonal. Conc: 1mg/ml Company: Abcam Order number: ab59256</p> <p>Detection System: ZytoChem Plus HRP Polymer System (Mouse/Rabbit) (Zytomed; No. POLHRP-100)</p> <p>Chromogen Substrate Solution: Liquid DAB+ Substrate Chromogen System (Dako; Order No. K3468).</p>	<p>Primary antibody: Anti RxR alpha; clone K8508 (mouse IgG2a); Conc: 1 mg/ml. Company: Perseus Proteomics Order number: PP-K8508-10</p> <p>Detection system: Vectastain Elite mouse -IgG kit (Linaris; No.PK-6102).</p> <p>Chromogen Substrate Solution: Liquid DAB+ Substrate Chromogen System (Dako; Order No.K3468).</p>
Staining Protocol	<ol style="list-style-type: none"> 1. Deparaffinize in xylene 2. Blocking: 20 min in 3% H₂O₂ in methanol. 3. Demask by heat pretreatment in pressure cooker with sodium citrate buffer pH 6.0 4. 5 min Blocking Solution. 5. primary antibody 16h overnight at 4°C; dilution: 1:100 in PBS 6. 30 min HRP polymer 7. 30 sec. substrate staining with DAB 8. 2 min. counterstaining 9. bluing for 5 min in tap water 10. cover with "Eukitt" 	<ol style="list-style-type: none"> 1. Deparaffinize in xylene 2. Blocking: 20 min in 3% H₂O₂ in methanol. 3. Demask by heat pretreatment in pressure cooker with sodium citrate buffer pH 6.0 4. 3 min. Power Block (BioGenex; No.HK0851008) 5. 4°C overnight (16h): primary antibody Dil.: 1:200 in in PBS 6. 30 min secondary antibody = biotinylated Link-Ak, which binds the ABC complex 7. 30 min ABC complex 8. 1 min substrate staining with DAB+Chromogen 9. 1 min. counterstaining 10. bluing for 3 min in tap water. 11. Covering with "Eukitt"
Staining	nucleus and cytoplasm	nucleus and cytoplasm

Supplementary Figure 1


A: RXR in normal breast tissue




B: PPAR in normal breast tissue




Supplementary figure 2



A: Nuclear RXR expression



B: Nuclear PPAR γ expression



C: Combined Nuclear expression RXR and PPAR γ

Supplementary Table S2 (belonging to Figure 2A).

Subgroups	Total number of cases	Estimate of survival time in years
PPARg low/RXRneg	49	8,817
PPARg low/RXRpos.	70	8,603
PPARg high/RXRneg.	46	8,508
PPARg high/RXRpos.	85	7,704
overall	250	8,311

Supplementary Table S3 (belonging to Figure 2B).

Subgroups	Total number of cases	Estimate of survival time in years
Other cases	165	8,64
PPARg high/RXRpos.	85	7,704
overall	250	8,311

Supplementary Table S4 (belonging to Figure 3A).

Subgroups	Total number of cases	Estimate of survival time in years
PPARg low/RXRneg	49	5,299
PPARg low/RXRpos.	70	5,412
PPARg high/RXRneg.	46	5,366
PPARg high/RXRpos.	85	4,169
overall	250	4,943

Supplementary Table S5 (belonging to Figure 3B).

Subgroups	Total number of cases	Estimate of survival time in years
Other cases	165	5,36
PPARg high/RXRpos.	85	4,169
overall	250	4,943

Supplementary Table S6 (belonging to Figure 3C).

Subgroups	Total number of cases	Estimate of survival time in years
Other cases	136	5,369
PPARg high/RXRpos.	63	4,353
overall	199	5,04

Supplementary Table S7 (belonging to Figure 3D).

Subgroups	Total number of cases	Estimate of survival time in years
Other cases	82	5,591
PPARg high/RXRpos.	33	4,137
overall	115	5,155